Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS／Janssen Holds "Dodge Ball" Event to Recruit New Graduates
November 5, 2007
- NEW PRODUCTS／Travatanz Ophthalmic Solution 0.004%: Alcon Japan
November 5, 2007
- REGULATORY NEWS IN BRIEF
November 5, 2007
- EPS Ties Up with CCPIE to Help Japanese Drug Firms Enter Chinese Market
November 5, 2007
- Korosho Proposes Revisions of NHI Pricing Rules
November 5, 2007
- J-TEC Aims at \1 Bil. with Japan's First Cultured Autologous Epidermis
November 5, 2007
- Conclusion Not yet Drawn on Causal Relation between Tamiflu and Abnormal Behavior
November 5, 2007
- Korosho Proposes More Fees for Treatment of Mental Illness
November 5, 2007
- Korosho to Order Revision of Package Insert for All Antidepressants
November 5, 2007
- Chugai to Place Top Priority on Proper Use of Tarceva
November 5, 2007
- Telavancin Received FDA Approvable Letter: Astellas
November 5, 2007
- Chugai's Operating Profits Up 24% in First 3 Qtr
November 5, 2007
- Nexavar, Zevalin, Gracevit, Prezista Recommended for Approval
November 5, 2007
- SEMINAR
November 5, 2007
- Lonasen, Clexane, Amage Recommended for Approval
November 5, 2007
- Korosho Found to Have Identifying Information on 118 Hepatitis C Patients
November 5, 2007
- BUSINESS NEWS IN BRIEF
November 5, 2007
- Gastric Cancer GL Stress Use of TS-1 for Inoperable Patients
November 5, 2007
- Kirin HD-Kyowa Hakko Deal Beneficial for Kirin HD, Neutral for Kyowa Hakko's Shareholders: DIR Report
November 5, 2007
- Defensive Factor Enhancing Agents Not Recommended after Endoscopic Therapy
November 5, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…